Home Cart Sign in  
Chemical Structure| 182349-12-8 Chemical Structure| 182349-12-8

Structure of Rupatadine Fumarate
CAS No.: 182349-12-8

Chemical Structure| 182349-12-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rupatadine fumarate is an inhibitor of PAFR and histamine (H1) receptor with Ki of 550 nM and 102 nM, respectively.

Synonyms: UR-12592 Fumarate; Rupatadine (fumarate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rupatadine Fumarate

CAS No. :182349-12-8
Formula : C30H30ClN3O4
M.W : 532.03
SMILES Code : CC1=CN=CC(CN2CC/C(CC2)=C3C4=CC=C(Cl)C=C4CCC5=CC=CN=C5\3)=C1.O=C(O)/C=C/C(O)=O
Synonyms :
UR-12592 Fumarate; Rupatadine (fumarate)
MDL No. :MFCD00926499
InChI Key :JYBLCDXVHQWMSU-WLHGVMLRSA-N
Pubchem ID :6449107

Safety of Rupatadine Fumarate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Rupatadine Fumarate

GPCR

Isoform Comparison

Biological Activity

Target
  • H1 receptor

    Histamine H1 receptor, Ki:102 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical vein endothelial cells (HUVEC) 500 ng/ml 1 hour To evaluate the effects of Rupatadine on dengue sera-induced endothelial permeability. Results showed that Rupatadine significantly reduced the effects of acute dengue sera on the expression of tight junction protein ZO-1 and trans-endothelial electrical resistance (TEER) in HUVEC cells. Sci Rep. 2018 Mar 1;8(1):3857
Ltk7 cells 0.01, 1 and 20 µM 4 minutes to 10 minutes To study the blocking effects of Rupatadine on hKv1.5 channels, results showed that Rupatadine blocked hKv1.5 channels in a concentration-dependent manner (KD=2.4±0.7 μM) and slowed the deactivation of tail currents. Br J Pharmacol. 1999 Nov;128(5):1071-81
HEK293T cells 6 nM 6 hours Determination of Rupatadine's residence time at the H1R using [3H]levocetirizine competitive association experiments. Results indicated that Rupatadine has a residence time exceeding 300 min, at least 10-fold longer than desloratadine. J Med Chem. 2019 Jul 25;62(14):6630-6644
TOV 112D 30 µM 72 hours To evaluate the inhibitory effect of rupatadine on ovarian cancer cell proliferation. Results showed that rupatadine significantly inhibited the proliferation of TOV 112D cells. Cells. 2021 Sep 7;10(9):2337
ES-2 30 µM 72 hours To evaluate the inhibitory effect of rupatadine on ovarian cancer cell proliferation. Results showed that rupatadine significantly inhibited the proliferation of ES-2 cells. Cells. 2021 Sep 7;10(9):2337
UWB1.289 30 µM 72 hours To evaluate the inhibitory effect of rupatadine on ovarian cancer cell proliferation. Results showed that rupatadine significantly inhibited the proliferation of UWB1.289 cells. Cells. 2021 Sep 7;10(9):2337
OVCAR-3 30 µM 72 hours To evaluate the inhibitory effect of rupatadine on ovarian cancer cell proliferation. Results showed that rupatadine significantly inhibited the proliferation of OVCAR-3 cells. Cells. 2021 Sep 7;10(9):2337

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice DENV-2 infection model Intraperitoneal 0.8 and 3 mg/kg Administered 30 minutes post-infection, monitored for 24 hours To assess the effect of Rupatadine in reducing vascular leak in a dengue-infected mouse model. Results demonstrated that Rupatadine significantly inhibited the increased haematocrit in dengue-infected mice, showing dose-dependency. Sci Rep. 2018 Mar 1;8(1):3857
Apoe-/- female mice Atherosclerosis model Dietary administration 170 mg/kg diet 12 weeks To evaluate the potential beneficial effects of Rupatadine on atherosclerosis development. Results showed that Rupatadine treatment led to an approximately 22% increase in aortic sinus plaque area and a significant increase in T lymphocyte numbers in the plaque and myocardial parenchyma surrounding the aortic sinus. Thromb Haemost. 2022 May;122(5):853-856
Wistar rats DEN-induced liver fibrosis model Oral 4 mg/kg/day Once daily for 4 weeks To assess the potential therapeutic effect of Rupatadine in DEN-induced liver fibrosis and to explore its possible mechanistic actions. Results showed that RUP ameliorated changes in body weights, liver indices, liver function enzymes, and histopathological alterations induced by DEN. Additionally, RUP amended oxidative stress, inhibited PAF/NF-κB p65-induced inflammation, and prevented TGF-β1 elevation and HSCs activation. Moreover, RUP exerted significant anti-fibrotic and anti-angiogenic effects by suppressing Hh and HIF-1α/VEGF signaling pathways. Inflammopharmacology. 2023 Apr;31(2):845-858
Wistar albino rats Isoproterenol-induced heart failure model Oral 4 mg/kg/day Once daily for 14 days To assess the possible protection afforded by rupatadine against isoproterenol-induced heart failure in rats and to explore the role of PI3k/Akt as a possible mechanistic pathway. Results showed that rupatadine significantly improved electrocardiographic and echocardiographic measurements, prevented the marked elevation of PAF and oxidative stress, and inhibited the production of Th17-promoting cytokines (IL-6, IL-23, and TGF-β). Front Pharmacol. 2021 Apr 30;12:651150

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00199238 URTICARIA PHASE2 TERMINATED 2004-09-27 Hospital Saint Louis, Paris Ce... More >>dex 10, 75475, France Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.40mL

1.88mL

0.94mL

18.80mL

3.76mL

1.88mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Queralt M, Brazis P, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000 Jul;49(7):355-60.

[2]Merlos M, Giral M, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997 Jan;280(1):114-21.

[3]Nettis E, Delle Donne P, Di Leo E, Calogiuri GF, Ferrannini A, Vacca A. Rupatadine for the treatment of urticaria. Expert Opin Pharmacother. 2013 Sep;14(13):1807-13

[4]González-Núñez V, Bachert C, Mullol J. Rupatadine: global safety evaluation in allergic rhinitis and urticaria. Expert Opin Drug Saf. 2016 Oct;15(10):1439-48

[5]Mullol J, Bousquet J, Bachert C, Canonica GW, Giménez-Arnau A, Kowalski ML, Simons FE, Maurer M, Ryan D, Scadding G. Update on rupatadine in the management of allergic disorders. Allergy. 2015 Jan;70 Suppl 100:1-24

[6]Abajian M, Curto-Barredo L, Krause K, Santamaria E, Izquierdo I, Church MK, Maurer M, Giménez-Arnau A. Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria. Acta Derm Venereol. 2016 Jan;96(1):56-9

[7]Malavige GN, Wijewickrama A, Fernando S, Jeewandara C, Ginneliya A, Samarasekara S, Madushanka P, Punchihewa C, Paranavitane S, Idampitiya D, Wanigatunga C, Dissanayake H, Prathapan S, Gomes L, Aman SAB, John AS, Ogg GS. A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection. Sci Rep. 2018 Mar 1;8(1):3857

 

Historical Records

Categories